Nautilus Biotechnology Inc
NASDAQ:NAUT
Decide at what price you'd be comfortable buying and we'll help you stay ready.
|
Johnson & Johnson
NYSE:JNJ
|
US |
|
Berkshire Hathaway Inc
NYSE:BRK.A
|
US |
|
Bank of America Corp
NYSE:BAC
|
US |
|
Mastercard Inc
NYSE:MA
|
US |
|
UnitedHealth Group Inc
NYSE:UNH
|
US |
|
Exxon Mobil Corp
NYSE:XOM
|
US |
|
Pfizer Inc
NYSE:PFE
|
US |
|
Nike Inc
NYSE:NKE
|
US |
|
Visa Inc
NYSE:V
|
US |
|
Alibaba Group Holding Ltd
NYSE:BABA
|
CN |
|
JPMorgan Chase & Co
NYSE:JPM
|
US |
|
Coca-Cola Co
NYSE:KO
|
US |
|
Verizon Communications Inc
NYSE:VZ
|
US |
|
Chevron Corp
NYSE:CVX
|
US |
|
Walt Disney Co
NYSE:DIS
|
US |
|
PayPal Holdings Inc
NASDAQ:PYPL
|
US |
Nautilus Biotechnology Inc
Other Long-Term Assets
Nautilus Biotechnology Inc
Other Long-Term Assets Peer Comparison
Competitors Analysis
Latest Figures & CAGR of Competitors
| Company | Other Long-Term Assets | CAGR 3Y | CAGR 5Y | CAGR 10Y | ||
|---|---|---|---|---|---|---|
|
|
Nautilus Biotechnology Inc
NASDAQ:NAUT
|
Other Long-Term Assets
$1.2m
|
CAGR 3-Years
2%
|
CAGR 5-Years
1%
|
CAGR 10-Years
N/A
|
|
|
Thermo Fisher Scientific Inc
NYSE:TMO
|
Other Long-Term Assets
$6B
|
CAGR 3-Years
15%
|
CAGR 5-Years
19%
|
CAGR 10-Years
19%
|
|
|
Danaher Corp
NYSE:DHR
|
Other Long-Term Assets
$3B
|
CAGR 3-Years
-5%
|
CAGR 5-Years
9%
|
CAGR 10-Years
11%
|
|
|
Waters Corp
NYSE:WAT
|
Other Long-Term Assets
$307.8m
|
CAGR 3-Years
17%
|
CAGR 5-Years
16%
|
CAGR 10-Years
8%
|
|
|
Agilent Technologies Inc
NYSE:A
|
Other Long-Term Assets
$886m
|
CAGR 3-Years
8%
|
CAGR 5-Years
9%
|
CAGR 10-Years
14%
|
|
|
IQVIA Holdings Inc
NYSE:IQV
|
Other Long-Term Assets
$862m
|
CAGR 3-Years
13%
|
CAGR 5-Years
12%
|
CAGR 10-Years
19%
|
|
Nautilus Biotechnology Inc
Glance View
Nautilus Biotechnology, Inc. operates as a life sciences company. The company is headquartered in Seattle, Washington and currently employs 113 full-time employees. The company went IPO on 2020-08-07. The firm is engaged in creating a platform technology for quantifying and unlocking the complexity of the human proteome. The firm focused on transforming the field of proteomics by democratizing access to the proteome and enabling fundamental advancements across human health and medicine. Its platform end-to-end solution comprised of the proteome analysis system, consumables, and software. The firm is developing a prototype of a single-molecule instrument, Proteomic Analysis System. The Company’s Proteomic Analysis Platform leverages a nanofabricated, single-molecule protein array, multi-cycle imaging, and machine learning analysis to identify and measure the proteome with sensitivity and scale.
See Also
What is Nautilus Biotechnology Inc's Other Long-Term Assets?
Other Long-Term Assets
1.2m
USD
Based on the financial report for Dec 31, 2025, Nautilus Biotechnology Inc's Other Long-Term Assets amounts to 1.2m USD.
What is Nautilus Biotechnology Inc's Other Long-Term Assets growth rate?
Other Long-Term Assets CAGR 5Y
1%
Over the last year, the Other Long-Term Assets growth was 0%. The average annual Other Long-Term Assets growth rates for Nautilus Biotechnology Inc have been 2% over the past three years , 1% over the past five years .
